Related Experiment Video
Updated: Sep 17, 2025
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
Update Gynecologic Malignancies 2025 - Expert Opinion on Systemic Therapy for Early and Advanced Gynecological
Julius Emons1,2,3,4, Julia Gocke1,2,3,4, Carla Schulmeyer1,2,3,4
1Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Abstract:
There have been major changes in the understanding of gynecologic malignancies in recent years, leading to new therapy options and subsequently to greater responsibilities for every professional treating those patients. The most significant therapeutic advances were achieved with checkpoint inhibitors (CPI), especially for endometrial and cervical cancer. In ovarian cancer the dominant and most important new substances are poly (ADP-ribose) polymerase inhibitors (PARPi). This review aims to summarize the latest studies and developments in the therapeutic landscape of endometrial, ovarian, and cervical cancer. The treatment of advanced endometrial cancer has changed significantly with the introduction of CPI such as dostarlimab (RUBY trial), durvalumab (DUO-E trial) and pembrolizumab (Keynote-868 trial). For ovarian cancer PARPi have shown substantial PFS benefits in key approval trials, including PRIMA for niraparib, PAOLA for olaparib, and ATHENA-MONO for rucaparib. These findings have established PARPi as the standard of care in maintenance therapy. Overall survival (OS) data for PRIMA and PAOLA are now available and are analyzed and placed into context in this article. Furthermore, mirvetuximab soravtansine is the first antibody-drug conjugate (ADC) approved in Germany for platinum-resistant ovarian cancer for patients with folate receptor alpha expression. The Keynote-A18 and BEATcc trials have opened new options for the utilization of immuno-oncology in cervical cancer treatment. Along with new therapeutic options, new biomarkers have also become part of daily clinical practice as predictive and prognostic factors as well as forming the basis for targeted personalized medicine. The use of CPI is revolutionizing the treatment of all gynecologic cancers and offers significant benefits for progression-free survival (PFS) and OS in most therapy regimens. With the increased use of ADCs, this is not the end of these developments. Therapy algorithms from a certified German oncology center are developed and presented in this article.
Insights
Checkpoint inhibitors (CPI) and poly (ADP-ribose) polymerase inhibitors (PARPi) are revolutionizing gynecologic cancer treatment, improving progression-free survival (PFS) and overall survival (OS). New antibody-drug conjugates (ADCs) also offer novel therapeutic avenues.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Clinical Therapeutics
Background:
- Recent advancements in understanding gynecologic malignancies have led to novel therapeutic strategies.
- Checkpoint inhibitors (CPI) and poly (ADP-ribose) polymerase inhibitors (PARPi) represent significant breakthroughs in treatment.
- Emerging antibody-drug conjugates (ADCs) are expanding treatment options for specific gynecologic cancers.
Purpose of the Study:
- To review and synthesize the latest developments in the therapeutic landscape of endometrial, ovarian, and cervical cancers.
- To contextualize the impact of novel agents like CPI, PARPi, and ADCs on patient outcomes.
- To present updated therapy algorithms based on recent clinical trial data from a certified German oncology center.
Main Methods:
- Comprehensive literature review of recent studies and clinical trials focusing on gynecologic malignancies.
- Analysis of pivotal trial data (e.g., RUBY, DUO-E, Keynote-868, PRIMA, PAOLA, ATHENA-MONO, Keynote-A18, BEATcc).
- Integration of biomarker data and their role in personalized medicine for gynecologic cancers.
Main Results:
- Checkpoint inhibitors (CPI) have significantly altered the treatment of advanced endometrial and cervical cancers, improving progression-free survival (PFS).
- Poly (ADP-ribose) polymerase inhibitors (PARPi) are established as standard maintenance therapy for ovarian cancer, demonstrating substantial PFS benefits.
- Mirvetuximab soravtansine (ADC) is approved for platinum-resistant ovarian cancer with folate receptor alpha expression; overall survival (OS) data for PARPi are now available.
Conclusions:
- Checkpoint inhibitors (CPI) are revolutionizing the treatment of gynecologic cancers, offering significant improvements in PFS and OS.
- PARPi have become a cornerstone in ovarian cancer maintenance therapy, with emerging data on overall survival.
- The advent of ADCs and continued research in immuno-oncology promise further advancements in personalized medicine for gynecologic malignancies.
More Related Videos
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
05:52Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy